Abiopharma

🔍 TABUTEAU HERRIOT (Executive)

Company: Axsome Therapeutics, Inc. (AXSM)

Report Date: 2026-06-09

Detailed Transactions and Holdings:

• Acquired 49,670 shares of Common Stock at $4.95 per share (Direct)
  Date: 2026-06-09 | Code: M | equity_swap_involved: false | shares_owned_after: 56,899.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 49,670 shares of Common Stock at $241.01 per share (Direct)
  Date: 2026-06-09 | Code: S | equity_swap_involved: false | shares_owned_after: 7,229.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-09 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 7,344,500.00 | Footnotes: F5
• Sold 49,670 shares of Stock Option (Right to Buy) at $241.01 per share (Derivative)
  Date: 2026-06-09 | Code: M | Expires: 2027-03-15 | Exercise: 2018-03-15 | equity_swap_involved: false | shares_owned_after: 99,330.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.
• F2: Such transaction was pursuant to a pre-approved 10b5-1 plan.
• F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
• F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $236.11 and $244.13.
• F5: Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.